scholarly journals EVALUATION OF EXTRAPLEURAL PNEUMONOLYSIS AND PARAFFIN PLOMBAGE FOR CHRONIC PULMONARY DISEASE

1950 ◽  
Vol 19 (4) ◽  
pp. 629-642
Author(s):  
H. Ryerson Decker
Keyword(s):  
Pulmonary Disease ◽  
Chronic Pulmonary Disease

Characteristics and outcomes of acute COVID-19 infection in paediatric and young adult patients with underlying cardiac disease

2021 ◽  
pp. 1-7
Author(s):  
Joshua M. Fisher ◽  
Sarah Badran ◽  
John T. Li ◽  
Jodie K. Votava-Smith ◽  
Patrick M. Sullivan
Keyword(s):  
Risk Factors ◽  
Young Adult ◽  
Pulmonary Disease ◽  
Cardiac Disease ◽  
Single Ventricle ◽  
Cardiac Risk ◽  
Adult Patients ◽  
Chronic Pulmonary Disease ◽  
Cardiac Risk Factors ◽  
Increased Risk

Abstract Objective To describe outcomes of acute coronavirus disease 2019 in paediatric and young adult patients with underlying cardiac disease and evaluate the association between cardiac risk factors and hospitalisation. Study design We conducted a retrospective single-institution review of patients with known cardiac disease and positive severe acute respiratory syndrome coronavirus 2 RT-PCR from 1 March, 2020 to 30 November, 2020. Extracardiac comorbidities and cardiac risk factors were compared between those admitted for coronavirus disease 2019 illness and the rest of the cohort using univariate analysis. Results Forty-two patients with a mean age of 7.7 ± 6.7 years were identified. Six were 18 years of age or more with the oldest being 22 years of age. Seventy-six percent were Hispanic. The most common cardiac diagnoses were repaired cyanotic (n = 7, 16.6%) and palliated single ventricle (n = 7, 16.6%) congenital heart disease. Fourteen patients (33.3%) had underlying syndromes or chromosomal anomalies, nine (21%) had chronic pulmonary disease and eight (19%) were immunosuppressed. Nineteen patients (47.6%) reported no symptoms. Sixteen (38.1%) reported only mild symptoms. Six patients (14.3%) were admitted to the hospital for acute coronavirus disease 2019 illness. Noncardiac comorbidities were associated with an increased risk of hospitalisation (p = 0.02), particularly chronic pulmonary disease (p = 0.01) and baseline supplemental oxygen requirement (p = 0.007). None of the single ventricle patients who tested positive required admission. Conclusions Hospitalisations for coronavirus disease 2019 were rare among children and young adults with underlying cardiac disease. Extracardiac comorbidities like pulmonary disease were associated with increased risk of hospitalisation while cardiac risk factors were not.

scholarly journals Statin for Tuberculosis and Pneumonia in Patients with Asthma–Chronic Pulmonary Disease Overlap Syndrome: A Time-Dependent Population-Based Cohort Study

2018 ◽  
Vol 7 (11) ◽  
pp. 381 ◽  
Author(s):  
Jun-Jun Yeh ◽  
Cheng-Li Lin ◽  
Chung-Y. Hsu ◽  
Zonyin Shae ◽  
Chia-Hung Kao
Keyword(s):  
Pulmonary Disease ◽  
Inhaled Corticosteroids ◽  
Population Based ◽  
Overlap Syndrome ◽  
Time Dependent ◽  
Research Database ◽  
Chronic Pulmonary Disease ◽  
Oral Steroids ◽  
Taiwan National Health Insurance ◽  
Study Participants

We investigated the effects of statins on tuberculosis (TB) and pneumonia risks in asthma–chronic pulmonary disease overlap syndrome (ACOS) patients. We extracted data of patients diagnosed as having ACOS during 2000–2010 from the Taiwan National Health Insurance Research Database and divided them into statin users and nonusers. All study participants were followed up from the index date until death, withdrawal from insurance, or TB and pneumonia occurred (31 December 2011). The cumulative TB and pneumonia incidence was analyzed using Cox proportional regression analysis with time-dependent variables. After adjustments for multiple confounding factors including age, sex, comorbidities, and use of medications [statins, inhaled corticosteroids (ICSs), or oral steroids (OSs)], statin use was associated with significantly lower TB [adjusted hazard ratio (aHR) 0.49, 95% confidence interval (CI) 0.34–0.70] and pneumonia (aHR 0.52, 95% CI 0.41–0.65) risks. Moreover, aHRs (95% CIs) for statins combined with ICSs and OSs were respectively 0.60 (0.31–1.16) and 0.58 (0.40–0.85) for TB and 0.61 (0.39–0.95) and 0.57 (0.45–0.74) for pneumonia. Thus, statin users had lower TB and pneumonia risks than did nonusers, regardless of age, sex, comorbidities, and ICS or OS use. Pneumonia risk was lower among users of statins combined with ICSs or Oss and TB risk was lower among the users of statins combined with OSs.

ADVERSE REACTIONS TO TETRACYCLINE, PENICILLIN AND AN OLEANDOMYCIN-PENICILLIN MIXTURE USED IN THE LONG-TERM THERAPY OF CHRONIC PULMONARY DISEASE

1962 ◽  
Vol 243 (3) ◽  
pp. 341-353 ◽  
Author(s):  
Solomon Sobel ◽  
Edward A. Lichter ◽  
J Calvin Davis ◽  
Harry F. Dowling ◽  
Mark H. Lepper ◽  
...  
Keyword(s):  
Pulmonary Disease ◽  
Adverse Reactions ◽  
Term Therapy ◽  
Chronic Pulmonary Disease ◽  
Long Term Therapy

scholarly journals Multimorbidity of Four Cardiometabolic and Chronic Pulmonary Disease Groups: Prevalence and Attributable Fraction in US Adults, 2007–2012

2017 ◽  
Vol 7 (1) ◽  
pp. 22-32 ◽  
Author(s):  
Lisa R. Staimez ◽  
Melissa Y. Wei ◽  
Min Kim ◽  
K. M. Venkat Narayan ◽  
Sharon H. Saydah
Keyword(s):  
Risk Factors ◽  
Pulmonary Disease ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Modifiable Risk Factors ◽  
Chronic Pulmonary Disease ◽  
Chronic Pulmonary Diseases ◽  
The Usa ◽  
Low Hdl ◽  
Obesity Hypertension

Background Cardiometabolic and chronic pulmonary diseases may be associated with modifiable risk factors that can be targeted to prevent multimorbidity. Objectives (i) Estimate the prevalence of multimorbidity across four cardiometabolic and chronic pulmonary disease groups; (ii) compare the prevalence of multimorbidity to that of one disease and no disease; and (iii) quantify population attributable fractions (PAFs) for modifiable risk factors of multimorbidity. Design Data from adults aged 18–79 years who participated in the US National Health and Nutrition Examination Survey 2007–2012 were examined. Multimorbidity was defined as ≥2 co-occurring diseases across four common cardiometabolic and chronic pulmonary disease groups. Multivariate-adjusted PAFs for poverty, obesity, smoking, hypertension, and low high-density lipoprotein (HDL) cholesterol were estimated. Results Among 16,676 adults, the age-standardized prevalence of multimorbidity was 9.3%. The occurrence of multimorbidity was greater with age, from 1.5% to 5.9%, 15.0% and 34.8% for adults aged 18–39, 40–54, 55–64 and 65–79 years, respectively. Multimorbidity was greatest among the poorest versus non-poorest adults and among blacks versus other races/ethnicities. Multimorbidity was also greater in adults with obesity, hypertension, and low HDL cholesterol. Risk factors with greatest PAFs were hypertension (38.8%; 95% confidence interval [CI] 29.4–47.4) and obesity (19.3%; 95% CI 10.2–28.2). Conclusions In the USA, 9.3% of adults have multimorbidity across four chronic disease groups, with a disproportionate burden among older, black, and poor adults. Our results suggest that targeting two intermediate modifiable risk factors, hypertension and obesity, might help to reduce the prevalence of multimorbidity in US adults.

Sign in / Sign up

Export Citation Format

Share Document